Proteostasis Therapeutics announces proposed public offering of common stock
Proteostasis announced it intends to offer and sell 9,000,000 shares of its common stock in an underwritten public offering. Proteostasis intends to grant underwriters a 30-day option to purchase up to an additional 1,350,000 shares of common stock. October 22, 2018